- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03001609
Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC
September 29, 2017 updated by: Hangzhou ACEA Pharmaceutical Research Co., Ltd.
An Open-Label, Non-Randomized, Single-Center Study to Determine the Absorption, Metabolism and Excretion of A Single Dose [14C] AC0010 in Patients With Advanced NSCLC
The purpose of this study is to investigate Pharmacokinetics parameters of a single dose [14C] AC0010 in male Patients With Advanced NSCLC.
Study Overview
Detailed Description
The purpose of this study is to investigate the Absorption, Metabolism, Excretion and Pharmacokinetics of a single dose [14C] AC0010 in male Patients With Advanced NSCLC.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- signed and dated informed consent
- histologically or cytologically confirmed diagnosis of local advanced or recurrent NSCLC
- failed to the treatment of EGFR-TKI and harbored T790M mutation
- male, Age 18~ 65, have a body mass index (BMI) >19 kg/m2
- ECOG PS:0-1,Life expectancy of more than 3 months
main organs function is normal, laboratory values as listed below: blood test without blood transfusion within 14 days
- Haemoglobin >100 g/L
- Absolute neutrophil count ≥2.0x10^9/L or WBC ≥3.5 x10^9/L
- Platelet count ≥ 80x10^9/L
- Total bilirubin ≤1.5xULN
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal (ULN)
- BUN≤1.5xULN
- Serum creatinine ≤1.5xULN or creatinine clearance ratio ≥60 mL/min
- Any prior treatment (chemotherapy, radiotherapy or surgery) must be completed over 4 weeks(target therapy over 2 weeks) from the screening; Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03)
- International normalized ratio (INR) ≤ 1.5
- Patients and their partners should be willing to use methods of contraception or total abstinence from start of dosing until 6 months after discontinuing of study treatment
Exclusion Criteria:
- Prior treated with AC0010 or allergic to drug or its formulation ingredients
- Patients receiving other anti-tumor therapy
- Impairment of GI disease, renal disorders or liver disease that may significantly alter the absorption and metabolic of AC0010 (e.g., Unable to swallow, liver, kidney or gastrointestinal partial resection, chronic diarrhea and intestinal obstruction)
- HCVAb positive, active hepatitis B (excluding HBV carriers), Hepatitis virus markers positive and receiving anti-virus drugs
- Meningeal metastasis; brain metastasis with whole brain radiotherapy; prior received hormones or mannitol for the brain metastasis
- Previous EGFR-TKI treatment related Interstitial lung disease history
- Known human immunodeficiency virus infection (HIV), other acquired or congenital immunodeficiency disease, or a history of organ transplantation
- Any severe and / or uncontrolled active infections
- Patients receiving concomitant immunosuppressive agents or high-dose corticosteroids
- Any severe and / or uncontrolled medical conditions
- Patients being treated with drugs recognized as being inhibitors or inducers of the liver isoenzyme in the last 4 weeks prior to registration in the current study
- Within 3 days prior to the treatment intaking of pitaya, pomelo, grapefruit, orange, mango and other fruit may affect drug metabolizing enzymes or juice
- Within 2 days prior to the treatment intaking of coffee, tea, cola, chocolate, or other caffeine containing beverages, alcoholic beverages and / or other alcoholic products
- Major surgery, incisional biopsy or traumatic injuries;
- Within 4 weeks prior to the screening patients with bleeding ≥ grade 3, non-healing wound, sever ulcer or bone fracture
- Patients received high dose irradiation treatment or other 14C-labeled drug within 1 year
- Known a history of alcoholism or drug abuse
- Nicotine or urine drug testing was positive
- Participate in any clinical trial within 4 weeks prior to the screening
- Investigator judgment that patient is unsuitable to participate in study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AC0010
each participant will be given a single dose of 14C-labeled AC0010
|
Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi[14C]
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics, Cumalative excretion and Metabolite of 14C-labeled AC0010
Time Frame: up to 8 Days
|
Pharmacokinetics of 14C-labeled AC0010 Radioactivity in whole blood and plasma,Cumulative excretion of 14C-labeled AC0010 radioactivity in feces and urine,Metabolite identification of 14C-labeled AC0010 in plasma, urine and feces
|
up to 8 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative analysis of plasma concentrations of unlabeled AC0010
Time Frame: up to 8 Days
|
Quantitative analysis of plasma concentrations of unlabeled AC0010 using a validated LC-MS/MS method
|
up to 8 Days
|
Number of adverse events (AE) experienced by patients
Time Frame: up to 8 Days
|
Number of adverse events (AE) experienced by patients to assess safety and tolerability
|
up to 8 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Feng Shao, Doctor, The First Affiliated Hospital with Nanjing Medical University
- Principal Investigator: Yongqian Shu, Doctor, The First Affiliated Hospital with Nanjing Medical University
- Principal Investigator: Lihua Bao, Doctor, The First Affiliated Hospital with Nanjing Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2016
Primary Completion (Actual)
August 1, 2017
Study Completion (Actual)
September 1, 2017
Study Registration Dates
First Submitted
December 19, 2016
First Submitted That Met QC Criteria
December 20, 2016
First Posted (Estimate)
December 23, 2016
Study Record Updates
Last Update Posted (Actual)
October 3, 2017
Last Update Submitted That Met QC Criteria
September 29, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Abivertinib
Other Study ID Numbers
- AC201606AVTN06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on AC0010
-
Hangzhou ACEA Pharmaceutical Research Co., Ltd.Guangdong Provincial People's Hospital; Acea Bio (Hangzhou) Co., Ltd.Active, not recruitingMetastatic Non-small Cell Lung CancerChina
-
Hangzhou ACEA Pharmaceutical Research Co., Ltd.CompletedCarcinoma,Non-Small-Cell LungChina
-
Hangzhou ACEA Pharmaceutical Research Co., Ltd.Guangdong Provincial People's HospitalUnknownMetastatic Non-small Cell Lung CancerChina
-
Sun Yat-sen UniversityHangzhou ACEA Pharmaceutical Research Co., Ltd.; Acea Bio (Hangzhou) Co., Ltd.UnknownNon-Small Cell Lung CancerChina
-
Hangzhou ACEA Pharmaceutical Research Co., Ltd.Unknown
-
Sorrento Therapeutics, Inc.Completed
-
Sorrento Therapeutics, Inc.Completed
-
Hangzhou ACEA Pharmaceutical Research Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesWithdrawn
-
Guangdong Association of Clinical TrialsChinese Thoracic Oncology GroupRecruitingCarcinoma, Non-Small-Cell LungChina